NICE says Tookad too expensive for prostate cancer
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
Read More
Tag: padeliporfin
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
